Biotech Exit Strategy Of Choice Is Acquisition, Not IPO, Investor Says
Executive Summary
Venture capital firms are increasingly shaping biotech companies to look like acquisition prospects from the outset, rather than candidates for initial public offerings, according to one investor's analysis
You may also be interested in...
Anti-Infectives Have Blockbuster Future Despite Personalized Medicine
Anti-infectives have the potential to remain top-selling products in the future even as personalized medicine curtails the number of therapies achieving blockbuster status, Lehman Brothers Vice Chairman Frederic Frank said
Anti-Infectives Have Blockbuster Future Despite Personalized Medicine
Anti-infectives have the potential to remain top-selling products in the future even as personalized medicine curtails the number of therapies achieving blockbuster status, Lehman Brothers Vice Chairman Frederic Frank said
J&J Acquires Phase III Antibiotic Doripenem; NDA Possible In 2006
Johnson & Johnson is acquiring the Phase III injectable carbapenem antibiotic doripenem via its $245 mil. purchase of Peninsula Pharmaceuticals